RAS Interaction with PI3K: More Than Just Another Effector Pathway
Top Cited Papers
Open Access
- 1 March 2011
- journal article
- research article
- Published by SAGE Publications in Genes & Cancer
- Vol. 2 (3), 261-274
- https://doi.org/10.1177/1947601911408079
Abstract
RAS proteins are small GTPases known for their involvement in oncogenesis: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.This publication has 99 references indexed in Scilit:
- Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapyLeukemia, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase productionThe FASEB Journal, 2001
- PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RASOncogene, 2000
- Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient miceNature, 1995
- The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogueNature, 1995
- The activation of phosphatidylinositol 3-kinase by RasCurrent Biology, 1994
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994